Working At Ossium


Who We Are

At Ossium, we believe that science is humanity’s best weapon in the fight against disease, and we embrace the challenge of mobilizing the world’s healthcare ecosystem to win that fight. In pursuit of this goal, we empower our employees, maintain the highest standards of excellence, and are a force for good.

Kevin Caldwell

CEO, Co-Founder & President


Listen to Kevin Speak About Our Vision

Principles


The values we live by

Impact

We are mission-driven and results-oriented. We believe that a healthier world is a better one and that our work should drive positive change.

Truth

Embracing the truth empowers us to learn from both our successes and our mistakes. We follow the data wherever it leads.

Ownership

We hold ourselves and each other to the highest bar. We care deeply about the work we do and know that even the smallest details can make a difference.

Inside Look


Day in the Life

Donor Field Services Managers

These donor tissue recovery experts work with our OPO partners to continuously improve our tissue recovery processes.  They are masters of Ossium’s recovery protocols and practices.

Cell Therapy Associates

These processing experts make our cell therapy products. They are skilled in tissue processing, cell processing, and cryopreservation.

Clinical Trial Project Managers

These project management maestros ensure that our clinical trials are run with diligent care.  They work with clinical investigators and healthcare institutions to manage our research.



Words from the Team

From the first day I started at Ossium, we had a clear goal to save lives. I come to work every day with that in mind. Getting to work on such a critical cause with the wonderful folks at Ossium makes this an incredible place to be.

Margie Mathewson

Vice President, Business Operations

Margie Mathewson

Vice President, Business Operations

Dr. Mathewson’s career has focused primarily on helping start-ups and small businesses build out robust operations, from internal structures and systems to external partnerships. Prior to joining Ossium, Dr. Mathewson was the 7th team member at Point, a FinTech start-up offering non-traditional options for home equity funding, where she led Business Operations. While there, she drove development of an underwriting process for nontraditional, complicated customers that allowed funding of Point’s initial set of homeowners, including the first to successfully exit the investment. She also communicated complex mathematical concepts to homeowners to educate them on the Point investment model and how their equity sale would work.

Dr. Mathewson also worked as a consultant for McKinsey & Company, where, among other projects, she helped develop a rapid growth strategy for a successful health system, overhauled a sales and supply chain planning process to improve communication and ensure every customer got what they ordered on time, and restructured the international sales team for a major global telecom. Dr. Mathewson completed her PhD at the University of California, San Diego, where she was an NSF Fellow and founded a successful mentorship program for first generation college students in engineering.

Meeting Erik a few years ago and exploring Ossium's mission is what motivated me to move from Europe and join Ossium. I am driven by developing new opportunities in cell therapy that save more lives, and being part of the amazing 'we can do it' Ossium team makes every day a joy.

Wa'el Al Rawashdeh

Director, Development

Wa'el Al Rawashdeh

Director, Development

Dr. Al Rawashdeh has an interdisciplinary career focusing on the clinical translation of cell therapies and development of molecular imaging platforms. Prior to joining Ossium, he held a number of critical roles at Miltenyi Biotec, a global market-leader in cell processing, that enabled the creation of a successful CAR T cell therapy program. Dr. Al Rawashdeh developed industry-leading non-clinical development (NCD) and molecular imaging platforms and led the in vivo NCD packages of the CAR T cell therapy program, which in 4 years resulted in 4 CIT approvals in Germany, 1 IND pivotal trial FDA application, and 1 successful approval of an ‘orphan drug’ by the EMA. Dr. Al Rawashdeh developed a novel animal model that permitted the approval of the first CAR T cell clinical trial in Europe targeting melanoma.

On the research front, Dr. Al Rawashdeh spearheaded the initiation of an industry-academia consortium that successfully secured a major grant of $1.6 million from the EU European Funding for Regional Development initiative to develop novel CAR T cell therapies against solid tumors and cell tracking strategies, and led the project up to the time of his departure in 2021, when he joined Ossium. .

As a postdoc at RWTH Aachen University, Germany’s top engineering university, Dr. Al Rawashdeh co-developed novel optical imaging technology that convinced MiLabs, a global leader in molecular imaging, to adopt the technology and build and commercialize a hybrid tomography system that generated over $10 million in sales to date. Furthermore, on the basis of his original research and project design where he recruited industry partners from Germany, Italy and the UK, he secured a $1 million grant from the European Union’s European Commission in the highly competitive multi-country BioPhotonics call.

Dr. Al Rawashdeh completed his BS from California State University, Fresno, and his MSc and Ph.D. from RWTH Aachen University.

What’s exciting about where we are at this time is that the regulatory space is new; the path and challenges ahead of us are just beginning. And our amazing team – they have the entrepreneurial spirit and drive to make it happen. I love it.

Oliver Cácananta

Senior Director, Regulatory Affairs

Oliver Cácananta

Senior Director, Regulatory Affairs

Mr. Cacananta is a 25-year veteran of the biopharmaceutical industry, having worked broadly with biologics, combination medical devices, and small molecule drugs. He has extensive involvement in collaboration or leadership of approved marketing and investigational regulatory filings (BLAs, MAAs, PMA, CE Mark, 510(k), NDA, INDs/IDEs as well as CMC and other pre- and post-approval commitment submissions) and in organizing and participating in various agency interactions (e.g., PDUFA meetings and advisory panel). His global experience spans multiple therapeutic areas, including vaccines for influenza and biodefense medical countermeasures, diabetes and other metabolic disorders, endovascular disease, blood pathogen reduction technologies, and cell therapy for ophthalmology and medical aesthetics, and diverse geographies, working with partners and agencies across North America, Europe, Asia-Pacific (primarily China, Japan, and Australia), South America, and Middle East-North Africa.

Mr. Cacananta’s career and contributions to research and science are rooted in the intersections of the biotech and pharmaceutical industry and the quality and regulatory pathways by which treatment and technological innovations reach patients. As a regulatory professional, his impact comes from shepherding research products through the product lifecycle, from clinical trials to market approval, all the while ensuring that products are safe and efficacious and are within the regulatory parameters set forth by governing agencies.

Mr. Cacananta has worked at a variety of large and small biotechnology companies, including Lineage Cell Therapeutics, Cerus Corporation, Medtronic, Amgen, Emergent BioSolutions, BioMarin Pharmaceuticals, and Chiron Corporation. He received his BS in Biological Sciences from California State University, East Bay, and MBA in Global Management from the University of Phoenix.




Open Positions

At Ossium, we’re always looking for talented, mission-driven people.


General Application

We’re always looking for talenting individuals who belive in our core mission. Don’t hesitate to fill out the General Application — we’ll find something for you to do!

Follow Us

Read our blog to see the latest Ossium updates.